Edwards Lifesciences Corp.EW is set to announce its second-quarter 2025 earnings on July 24, following the market’s closing.
In the most recent reported quarter, the company’s adjusted earnings per share amounted to 64 cents, surpassing the Zacks Consensus Estimate by 6.67%. The company exceeded expectations in two of the past four quarters and met them in the remaining two, with an average surprise of 3.49%.
Q2 Estimates
The Zacks Consensus Estimate for revenue stands at $1.49 billion, indicating an 8.9% decrease compared to the previous year’s reported amount.
The Zacks Consensus Estimate for net income of 62 cents per share shows a decrease of 11.4% compared to the same period last year.
Projected Changes in Outlook Before Edwards’ Second-Quarter Financial Results
Recent projections for earnings have stayed steady at 62 cents per share over the last 60 days.
Below is a short summary of the company’s advancements prior to this announcement.
Factors at Play
In the second quarter of 2025, theTranscatheter Aortic Valve Implantation (“TAVI”)The arm is expected to have shown a solid performance in the United States, driven by its leading SAPIEN 3 Ultra RESILIA platform. The ongoing growth of SAPIEN 3 Ultra RESILIA in Europe is anticipated to have boosted global results. The platform has achieved impressive patient results, and the trend is expected to continue as more facilities implement it. While we anticipate the company to have faced a challenging procedure growth climate and competition in Japan, it remains focused on tackling the considerable under-treatment of aortic stenosis within the country’s large elderly population.
During its last earnings call, Edwards mentioned that it encountered some regional differences even though it maintains a solid competitive advantage and consistent global pricing. This pattern is expected to have persisted in the second quarter, limiting the segment’s overall potential. Our model projects TAVR sales at $1.09 billion, representing a 5.2% increase compared to the previous year.
In the Transcatheter Mitral and Tricuspid Treatments (“TMTT”)The segment, which focuses on strength within the repair and replacement technology portfolio for both Mitral and Tricuspid valves, is expected to have contributed to Edwards’ results in the second quarter of 2025. The PASCAL repair system is anticipated to see growing use in the United States, Europe, and worldwide, due to its unique characteristics, resulting in broader implementation of the technology at both current and new facilities.
Furthermore, the commercial release of the EVOQUE tricuspid replacement system may have kept moving forward in the United States and Europe. By March, it received Medicare coverage under the final NCD for transcatheter tricuspid valve replacement, increasing availability.
Edwards has increased its 2025 sales forecast for this segment to $530-$550 million (previously $500 million), and we anticipate the company will have made significant progress in the upcoming quarter. Our model projects the TMTT business to generate revenues of $130.4 million, reflecting a 57.1% increase compared to the same period last year.
Lastly, Edwards’ Surgical Structural Heartcould have showcased a robust performance in the upcoming quarter, fueled by the worldwide acceptance of its high-end RESILIA line, such as MITRIS, INSPIRIS, and KONECT. The firm probably experienced favorable procedural growth across various regions for patients who benefit most from surgical treatment, including intricate and combined procedures. Additionally, the introduction of MITRIS in China, along with favorable responses from medical professionals, may have helped boost the second-quarter revenue.
Our model predicts the segment’s revenues at $263.1 million, indicating a slight increase of 6.2% compared to the same period last year.
Earnings Whispers for Edwards
Based on our established model, stocks rated Zacks Rank #1 (Strong Buy), #2 (Buy), or #3 (Hold), combined with a positive Earnings ESP, are more likely to exceed expectations, which is not the situation here, as shown below:
Earnings ESP: Edwards has an Earnings ESP of 0.00%. Discover the top stocks to buy or sell prior to their announcements using our Earnings ESP Filter.
Zacks RankThe company currently has a Zacks Rank of #2. You can view it herethe full list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are several medical stocks that may be worth looking into, as they possess the appropriate mix of factors to exceed earnings expectations during this reporting period:
CVS Health CVS currently has an Earnings ESP of +2.06% and holds a Zacks Rank of #1. The company is scheduled to announce its second-quarter 2025 earnings on July 31. You can view the full list of today’s Zacks #1 Rank stocks here.
CVS exceeded expectations in each of the past four quarters, with an average surprise of 18.08%. The Zacks Consensus Estimate for second-quarter EPS suggests a year-over-year decrease of 19.7%.
CencoraCOR has an Earnings ESP of +1.49% and holds a Zacks Rank of #2 currently. The firm is scheduled to announce its third-quarter fiscal 2025 earnings on August 6.
The company’s earnings exceeded expectations in each of the past four quarters, with an average surprise of 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS suggests a year-over-year growth of 13.2%.
Cardinal Health CAH currently has an Earnings ESP of +0.68% and holds a Zacks Rank of #2. The company is set to announce its fiscal fourth-quarter 2025 results on August 12.
CAH’s earnings exceeded expectations in each of the past four quarters, with an average surprise of 10.30%. The Zacks Consensus Estimate for the fourth-quarter fiscal EPS indicates a year-over-year increase of 1.3%.
This piece was first released on Zacks Investment Research ().
